Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group
- 5 January 2021
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 12 (1) , 39-47
Abstract
Psammaplin A (PsA) is a bromotyrosine disulfide dimer with histone deacetylase (HDAC) inhibition and acts through reduced monomer PsA-SH. We studied the connection of HDAC inhibition, cell growth inhibition, and apoptosis induction of PsA-SH by modifying the −SH group with deletion (6a) or replacement with hydroxamic acid (10b) or benzamide (12g). PsA-SH inhibits HDAC1/2/3 and 6a loses the HDAC inhibition ability. 10b inhibits HDAC1/2/3/6 while 12g shows selective inhibition of HDAC3. PsA-SH and 10b, but neither 6a nor 12g, induce apoptosis in human leukemia HL-60 cells associated with increased acetylation of Histone H3. PsA-SH and 10b inhibit growth of several solid tumor cell lines in vitro and Lewis lung cancer cell growth in vivo. PsA-SH is a simple scaffold for developing selective HDAC inhibitors and induces apoptosis through inhibiting HDAC1/2.Keywords
Funding Information
- Samuel Waxman Cancer Research Foundation
This publication has 34 references indexed in Scilit:
- Indole-Derived Psammaplin A Analogues as Epigenetic Modulators with Multiple Inhibitory ActivitiesJournal of Medicinal Chemistry, 2012
- Structure of HDAC3 bound to co-repressor and inositol tetraphosphateNature, 2012
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursEuropean Journal of Cancer, 2010
- Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivativesBioorganic & Medicinal Chemistry, 2009
- Chemical mechanisms of histone lysine and arginine modificationsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2009
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivoClinical Cancer Research, 2008
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysisThe Lancet Oncology, 2008
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomyBritish Journal of Cancer, 2008
- Psammaplin A is a natural prodrug that inhibits class I histone deacetylaseExperimental & Molecular Medicine, 2007
- Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysisBreast Cancer Research and Treatment, 2005